MAPK9 and Miyoshi myopathy: In line with that, upregulation of miR-202 in the presence of the drug Bortezomib inhibited MM cell survival more effectively compared to Bortezomib treatment alone, which involved the reactivation of the JNK/SAPK signaling pathway as the regulatory downstream target of miR-202 [79].